Recent News

• 04.25.2025 - Prelude Announces Presentations at 2025 AACR Annual Meeting
• 04.25.2025 - Prelude Announces Presentations at 2025 AACR Annual Meeting
• 04.25.2025 - Elucidating the Molecular Mechanism of Action of the First-in-Human SMARCA2 Selective Degrader PRT3789
• 04.25.2025 - Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.10.2025 - Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
• 03.10.2025 - Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
• 03.10.2025 - PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Advanced Solid Tumors With a SMARCA4 Mutation: Phase 1 Trial

Recent Filings

• 04.11.2025 - PRE 14A Other preliminary proxy statements
• 04.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.28.2025 - 8-K Current report
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - EX-99.1 EX-99.1
• 03.10.2025 - 8-K Current report